ClinicalTrials.gg
CompletedNCT04440956Updated Jun 22, 2020

An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours

An Early Phase 1 interventional study of 64Cu-SARTATE in Neuroendocrine Tumors, sponsored by Clarity Pharmaceuticals Ltd. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-22.

Sponsored by Clarity Pharmaceuticals Ltd · Early Phase 1, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 5 years after the study started (first participant enrolled May 2015, registered Jun 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The primary purpose of this study is to examine the safety and potential effectiveness of a drug molecule called 64Cu-SARTATE as a potential new way to detect neuroendocrine cancers.

02

Conditions studied

  • Neuroendocrine Tumors

Browse trials for

03

In context

Neuroendocrine Tumors

544 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

This study's enrollment of 10 is below the median of 41 across 388 interventional studies indexed under Neuroendocrine Tumors.

Browse Neuroendocrine Tumors studies →

Lead sponsor

Clarity Pharmaceuticals Ltd is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. Age greater than or equal to 18 years
  3. greater than or equal to 8 weeks
  4. Low and Intermediate Grade (Ki-67 index \<20%) neuroendocrine tumors (NET)
  5. At least one site of active somatostatin receptor positive , as demonstrated on the pre-study 68Ga-DOTATATE PET/CT scan performed as part of routine clinical care
  6. Subjects with an estimated (eGFR) greater than 60ml/min as measured using the MDRD formula (Modification of Diet in Renal Disease).
  7. (ECOG) performance score of 0-2

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding females
  2. Known sensitivity or allergy to somatostatin analogues
  3. Subjects who have received interventional treatment for their NET in the interval between 68Ga-DOTATATE PET/CT \& 64Cu-SARTATE PET/CT scan
  4. Treatment with long acting somatostatin analogues within 28 days prior to the administration of Product
  5. Treatment with short acting somatostatin analogues within 24hrs prior to the administration of Investigational Product
  6. greater than 0.44seconds as measured by screening
  7. Any serious medical condition which the investigator feels may interfere with the procedures or evaluations of the study
  8. Patients unwilling or unable to comply with protocol or with a history of non-compliance or inability to grant
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Early Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Intervention

    200MBq of 64Cu-MeCOSar-Octreotate ("64Cu-SARTATE") given as a single bolus intravenous injection.

    Drug: 64Cu-SARTATE

Interventions

  • 200MBq of 64Cu-MeCOSar-Octreotate ("64Cu-SARTATE") given as a single bolus intravenous injection and peptide mass will not exceed 10micrograms.

    Also known as: 64Cu-MeCOSar-Octreotate

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events related to 64Cu-SARTATE

    Occurrence of adverse clinical, biochemical or haematological events assessed for up to 1 week post administration of 64Cu-SARTATE.

    Time frame: 1 week post administration

  2. Percentage of injected 64Cu-SARTATE dose found in organs of interest

    Percentage of injected 64Cu-SARTATE dose found in organs of interest via whole body PET scan

    Time frame: At 30 minutes following administration

  3. Percentage of injected 64Cu-SARTATE dose found in organs of interest

    Percentage of injected 64Cu-SARTATE dose found in organs of interest via whole body PET scan

    Time frame: At 1 hour following administration

  4. Percentage of injected 64Cu-SARTATE dose found in organs of interest

    Percentage of injected 64Cu-SARTATE dose found in organs of interest via whole body PET scan

    Time frame: At 4 hours following administration

  5. Percentage of injected 64Cu-SARTATE dose found in organs of interest

    Percentage of injected 64Cu-SARTATE dose found in organs of interest via whole body PET scan

    Time frame: At 24 hours following administration

  6. Absorbed organ dose

    Absorbed organ doses expressed as micro Sv/MBq of administered 64Cu-SARTATE, and whole body dose expressed as milliSv/200MBq of administered dose as assessed using whole body PET scan (composite outcome)

    Time frame: At 30 minutes following administration

  7. Absorbed organ dose

    Absorbed organ doses expressed as micro Sv/MBq of administered 64Cu-SARTATE, and whole body dose expressed as milliSv/200MBq of administered dose as assessed using whole body PET scan (composite outcome)

    Time frame: At 1 hour following administration

  8. Absorbed organ dose

    Absorbed organ doses expressed as micro Sv/MBq of administered 64Cu-SARTATE, and whole body dose expressed as milliSv/200MBq of administered dose as assessed using whole body PET scan (composite outcome)

    Time frame: At 4 hours following administration

  9. Absorbed organ dose

    Absorbed organ doses expressed as micro Sv/MBq of administered 64Cu-SARTATE, and whole body dose expressed as milliSv/200MBq of administered dose as assessed using whole body PET scan (composite outcome)

    Time frame: At 24 hours following administration

Secondary outcomes

  1. Demonstration of known malignancy

    Whether 64Cu-SARTATE PET/CT scans demonstrate known sites of 68Ga-DOTATATE avid malignancy with equivalent or greater tumor to background ratios, where background uptake is that found in a non-tumor containing area of interest as decided upon by the nuclear medicine physician at the time of scan assessment.

    Time frame: 30 minutes, 1 hour, 4 hours and 24 hours following administration

  2. Uptake in non-physiological, non-tumor containing tissues

    Whether 64Cu-SARTATE PET/CT scans demonstrate any non-physiological, non-tumor containing tissues with uptake greater than 1.5 x that of the background, where background uptake is defined as in secondary endpoint.

    Time frame: 30 minutes, 1 hour, 4 hours and 24 hours following administration

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in Feb 2016, 9 months.

Of 54 phase 1 interventional studies under Neuroendocrine Tumors, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 75. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2020
First posted
Jun 22, 2020
StartActual
May 21, 2015
Primary completionActual
Feb 25, 2016
CompletionActual
Feb 25, 2016
Last update
Jun 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04440956
Lead sponsor
Clarity Pharmaceuticals Ltd
Responsible party
Sponsor
First posted
Jun 22, 2020
Start date
May 21, 2015
Primary completion
Feb 25, 2016
Completion
Feb 25, 2016
Last update
Jun 22, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 64Cu-SARTATE

Start the discussion